Raymond James analyst Steven Seedhouse reiterated an Outperform rating on CymaBay Therapeutic (NASDAQ: CBAY) noting that he is expecting a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE